Disclosures
Josep O. Dalmau, MD, PhD
Scientific Advisory Boards
SAGE therapeutics
Editorial Boards
Editor: Neurology® Neuroimmunology and Neuroinflammation; Annals Neurology
Patents
Patent for Ma2 autoantibody test: US 6,387,639; Issued May 14th, 2002. Patent for NMDA receptor autoantibody test: US 7,972,796 B2 July 5, 2011; European 2057466. Patent for GABAb receptor autoantibody test: US 8,685,656; European 2483417; Patents filed for GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test.
Publishing Royalties
Neurology- UpToDate, Wolters Kluwer contributing author, receive royalties Medlink Neurology contributing author, receive royalties
Consultancies
Advance Medical
Research Support, Commercial Entities
Research support (allosteric modulation of NMDAR) from SAGE Therapeutics
Research Support, Government Entities
-Instituto Carlos III/FEDER (FIS PI20/00197, CIBERER CB15/00010, Proyectos Integrados de Excelencia, PIE 16/00014 and AC18/00009). -Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), and CERCA Programme Generalitat de Catalunya -ERA-NET NEURON -La Caixa Foundation Health Research Award -Pablove Foundation Childhood Cancer Research Grant
Research Support, Foundations and Societies
Safra Foundation Sage therapeutics Cellex Foundation La Caixa Health Foundation
Royalty Payments, Technology or Inventions
Ma2 autoantibody test (tech/invention), Athena Diagostics via Memoral Sloan Kettering, current NMDA receptor, GABA(B) receptor autoantibody tests (tech/invention), Euroimmun, Inc via University of Pennsylvania, current GABA(A) receptor, DPPX and IgLON5 autoantibody tests (tech/invention), Euroimmun, Inc via Institucio Catalana de Recerca i Estudis Avancats (ICREA); Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), current